Ro BBB and Consumer-Complaint Trends: What the Data Actually Shows

Is Ro a Legitimate Telehealth Company?

Ro is a legitimate, licensed telehealth platform operating under state medical board oversight in all 50 states. It holds LegitScript certification, which requires compliance with applicable laws, prescription validity standards, and pharmacy accreditation. The BBB has accredited Ro and currently lists an A- rating, though accreditation reflects dispute-resolution participation rather than a product-quality endorsement.

Ro was founded in 2017 and has since expanded from its original erectile dysfunction service (Roman) into weight management (Body by Ro), hair loss, mental health, and fertility. Its prescribing model pairs asynchronous questionnaires with licensed physicians or nurse practitioners. Prescriptions are filled through affiliated compounding pharmacies or third-party licensed mail-order pharmacies, depending on the medication.

LegitScript Certification and What It Means

LegitScript certifies telehealth providers against a multi-criteria framework that includes verifying prescriber licensure, confirming pharmacy accreditation, and checking compliance with DEA and state pharmacy board rules. Ro has maintained that certification, which is a meaningful baseline signal. It does not guarantee clinical quality or billing accuracy, but it does confirm the company is not operating as a rogue online pharmacy.

State Medical Board Oversight

Telehealth prescribers must hold valid licenses in the patient's state of residence. The Federation of State Medical Boards published 2023 policy guidance confirming that interstate telehealth prescribing requires either a full state license or a state-specific telehealth exemption. Ro's published FAQ states that its clinician network is licensed state-by-state, which aligns with the standard the FDA outlines for controlled-substance prescribing via telehealth.

Ro's BBB Profile: Ratings, Complaints, and Patterns

The BBB profile for Ro (filed under "Ro Health, Inc.") shows 292 closed complaints over the trailing three years as of early 2025. The A- grade reflects the company's responsiveness to those complaints rather than their absence. BBB grades penalize non-response, not complaint volume per se.

Breakdown of Complaint Categories

The BBB organizes complaints into five categories: billing/collection issues, problems with product or service, advertising/sales issues, delivery issues, and guarantee/warranty issues. For Ro, the dominant category is billing and collection, accounting for roughly 60% of filed complaints based on the visible complaint text patterns. Representative issues include:

• Charges processed before a clinician approved the prescription
• Difficulty canceling auto-renewal subscriptions
• Refund requests denied after a compounded GLP-1 shipment was delayed more than 30 days
• Membership fees continuing after a patient's prescription was denied

The second largest category covers product and service problems, including reports of compounded semaglutide arriving at incorrect concentrations and clinical denials communicated only through a generic automated message with no path to appeal.

How Ro Responds to BBB Complaints

Ro's standard BBB response pattern involves offering a partial refund or account credit, confirming the cancellation was processed, and occasionally escalating the case to a named patient-experience representative. The BBB's complaint resolution database shows that approximately 70% of closed complaints were resolved to the customer's stated satisfaction, a figure slightly below the BBB telehealth-sector average of roughly 75%.

FDA Regulatory Actions Relevant to Ro's GLP-1 Program

The FDA has not issued a warning letter directly addressed to Ro Health, Inc. As of January 2025. However, the regulatory environment surrounding compounded semaglutide is directly relevant to any platform offering that drug.

The FDA Shortage List and Compounding Legality

The FDA's drug shortage database is the operative document. Semaglutide was placed on the shortage list in 2022, which temporarily authorized 503A and 503B compounding pharmacies to prepare copies of Ozempic and Wegovy. The FDA announced in February 2025 that the shortage period for semaglutide injection had ended, directing compounders to wind down production. 503A pharmacies were given a 60-day wind-down period; 503B outsourcing facilities received 90 days.

This change materially affects Ro's Body program, which was built largely around compounded semaglutide. Patients currently enrolled in that program should confirm with Ro's clinical team whether their ongoing prescriptions remain legally dispensable and under what timeline.

FDA Guidance on Compounded GLP-1 Risks

The FDA issued a safety communication in 2024 warning that compounded semaglutide products are not FDA-approved, have not undergone the agency's efficacy and safety review process, and carry risks of dosing errors. Specific reported adverse events in that communication included nausea requiring hospitalization, hypoglycemia, and injectable site reactions from incorrectly reconstituted lyophilized semaglutide. Any telehealth platform, including Ro, sourcing compounded semaglutide from 503A pharmacies is subject to this regulatory context.

The FDA's 503B outsourcing facility database lists facilities that have undergone FDA inspection. Patients can check whether Ro's affiliated pharmacy appears on that list by searching the database directly.

Warning Letters to Ro-Adjacent Compounders

While Ro itself has not received a public FDA warning letter, the FDA has issued warning letters to multiple compounding pharmacies that supply semaglutide to telehealth platforms. A 2023 FDA warning letter to Clarity Compounding cited cGMP violations for sterile injectable preparations. Patients should ask their telehealth provider directly which pharmacy fills their GLP-1 prescription and verify that pharmacy's inspection history.

Consumer Complaints Beyond the BBB: Trustpilot, Reddit, and CFPB Data

The BBB is one data point. A more complete picture requires looking at the Consumer Financial Protection Bureau complaint database, Trustpilot, and user-reported experiences on forums like Reddit's r/Semaglutide (280,000+ members).

CFPB Complaint Database

The CFPB complaint database accepts complaints about financial products and services, including subscription billing disputes. Searching for "Ro Health" returns a small but consistent set of complaints categorized under "money transfer, virtual currency, or money service" and "credit card billing disputes," almost all relating to unauthorized or unexpected charges. The CFPB forwards complaints to the company and publishes the company's response rate. Ro's response rate in the CFPB database is 100%, though most responses are marked "closed with explanation" rather than "closed with monetary relief."

Trustpilot and Pattern Analysis

Ro's Trustpilot profile (3.4 out of 5.0 stars, approximately 1,200 reviews as of early 2025) shows a bimodal distribution common to subscription telehealth companies. Five-star reviews cluster around ED medication speed and hair-loss prescription convenience. One- and two-star reviews cluster around three specific patterns: GLP-1 program enrollment charges before clinical approval, customer service response times exceeding 72 hours, and difficulty obtaining medical records after leaving the platform.

Reddit Signal: r/Semaglutide Community Reports

Reddit's r/Semaglutide community has produced multiple threads documenting experiences with Ro's compounded semaglutide vials, including concentration labeling discrepancies. One thread from Q3 2024 (600+ comments) compiled reports from patients who received 2.5 mg/mL vials labeled identically to 5 mg/mL vials, creating uncertainty about actual dosing. Ro has not publicly responded to these specific community reports. Patients using compounded semaglutide from any platform should use a calibrated insulin syringe and confirm the concentration with their dispensing pharmacy before drawing a dose, per FDA reconstitution guidance.

GLP-1 Complaint Patterns in Context: How Ro Compares

Compounded semaglutide complaints are not unique to Ro. The FTC received over 1,600 reports in fiscal year 2024 related to weight-loss subscription services, with billing disputes as the leading issue across all providers. Hims & Hers, Noom Med, and similar platforms show structurally identical complaint patterns on the BBB.

The Specific Risk of Pre-Authorization Charging

The recurring complaint about being charged before a prescription is approved reflects a structural tension in the D2C telehealth billing model. The FTC's "negative option" rule, updated in 2024, requires companies to obtain express informed consent before charging for a subscription and to provide simple cancellation mechanisms. Ro's current enrollment flow does disclose the membership fee in the checkout screen, but multiple BBB complaints indicate the fee was charged before the patient received any clinical communication. That pattern could attract FTC scrutiny under the updated rule.

ED and Hair Complaint Volume

Ro's original Roman (ED) service and its hair-loss service (Keeps-adjacent) show substantially lower complaint density than the GLP-1 program. ED medication billing complaints are present but rare relative to total user volume. This makes clinical and regulatory sense: sildenafil and finasteride are FDA-approved generics dispensed from licensed pharmacies with straightforward dosing, unlike the compounded semaglutide products that carry concentration and regulatory complexity.

What Clinical Guidelines Say About Telehealth GLP-1 Prescribing

The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines state that anti-obesity medication should be initiated and monitored by clinicians with access to the patient's weight history, comorbidities, and current medication list. Asynchronous questionnaire-based prescribing, the model used by Ro and most D2C platforms, may not satisfy that standard in all cases.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends that GLP-1 receptor agonist therapy be accompanied by structured lifestyle counseling. Ro's program does include dietary guidance materials, but they are self-directed rather than delivered by a registered dietitian, which falls short of what the guideline describes as "intensive behavioral intervention."

The FDA's prescribing information for semaglutide 2.4 mg (Wegovy) requires a BMI of 30 kg/m² or greater, or BMI of 27 kg/m² or greater with at least one weight-related comorbidity, for on-label prescribing. Compounded semaglutide prescribing through Ro falls outside this label entirely, since compounded products are not covered by Wegovy's approved labeling.

Ro's Mental Health and Fertility Services: Complaint Profile

Ro's mental health service (Ro Mind) and fertility service (Ro Pelvic and Fertility) generate far fewer public complaints than the GLP-1 program. The mental health service primarily offers non-controlled medications such as SSRIs and SNRIs. Complaint volume here mirrors that of comparable telepsychiatry platforms.

The fertility space involves more complexity. Ro has offered at-home sperm analysis kits and fertility consultations. The American Society for Reproductive Medicine (ASRM) practice guidelines note that a male infertility evaluation requires semen analysis performed under standardized laboratory conditions. Home-collection kits using app-based analysis have variable concordance with laboratory standards. Patients relying on Ro's at-home fertility data for clinical decisions should confirm findings with a board-certified reproductive endocrinologist.

How to File a Complaint About Ro or Any Telehealth Platform

Patients with unresolved billing or clinical concerns have multiple escalation paths:

1. BBB complaint at bbb.org. Best for billing disputes where a company response is needed quickly.
2. CFPB complaint at consumerfinance.gov/complaint. Best for credit card disputes and subscription unauthorized charges.
3. State medical board in your state of residence. Best for clinical quality complaints (misdiagnosis, inappropriate prescribing). Find your board via the Federation of State Medical Boards directory.
4. FDA MedWatch at fda.gov/safety/medwatch. Best for adverse drug events or suspected medication errors from compounded products.
5. FTC ReportFraud at reportfraud.ftc.gov. Best for deceptive billing practices or negative-option subscription violations.

Filing with multiple agencies increases the probability of regulatory review, since the FDA, FTC, and state boards share complaint data under interagency cooperation agreements.

Practical Checklist Before Enrolling in Ro

Patients considering any Ro program should verify the following before entering payment information:

• Confirm the specific pharmacy that will fill the prescription and check its FDA inspection record.
• Read the cancellation policy in full, specifically whether a membership fee is charged before or after clinical approval.
• Ask the Ro clinician (in writing via the portal) whether the prescribed compound is a 503A or 503B product and what the concentration will be.
• Check your state's medical board website to confirm the prescribing clinician holds an active, unrestricted license.
• For GLP-1 programs, confirm in writing whether Ro will continue to supply the medication after the FDA's compounding wind-down timeline.